Humacyte Presents Phase 3 Trial Data at ASN Kidney Week Highlighting ATEV Benefits for Women

Article summary

Humacyte reported new Phase 3 clinical trial data at ASN Kidney Week demonstrating that its Acellular Tissue Engineered Vessel (ATEV) offers significant advantages for women, including faster transition off catheters compared to traditional fistulas.